Factors Influencing Overall Survival Specific to Adult Low-grade Astrocytoma: APopulation-based Study

Clinical Oncology

Volumn 25, Issue 7, 2013, Pages 394-399

  Sahgal, A ^a,b   Ironside, S A ^c   Perry, J ^d   Mainprize, T ^d   Keith, J L ^d   Laperriere, N ^b   Tsao, M ^a   Paszat, L ^a,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Glioma; Low grade glioma; Low grade astrocytoma; Overall survival; Population based study; Prognostic factors

Indexed keywords

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; TUMOR BIOPSY;

ADULT; AGE FACTORS; ASTROCYTOMA; BIOPSY; BRAIN NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; ONTARIO; PROGNOSIS; REGISTRIES; SURVIVAL RATE;

EID: 84878654304     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.04.005     Document Type: Article

References (17)

1. Kaloshi G., Psimaras D., Mokhtari K., et al. Supratentorial low-grade gliomas in older patients. Neurology 2009, 73(24):2093-2098.
2. Pouratian N., Mut M., Jagannathan J., Lopes M.B., Shaffrey M.E., Schiff D. Low-grade gliomas in older patients: a retrospective analysis of prognostic factors. JNeurooncol 2008, 90(3):341-350.
3. Schomas D.A., Laack N.N., Brown P.D. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer 2009, 115(17):3969-3978.
4. Mathiesen T., Peredo I., Lonn S. Two-year survival of low-grade and high-grade glioma patients using data from the Swedish Cancer Registry. Acta Neurochir (Wien) 2011, 153(3):467-471.
5. Ishkanian A., Laperriere N.J., Xu W., et al. Upfront observation versus radiation for adult pilocytic astrocytoma. Cancer 2011, 117(17):4070-4079.
6. Okamoto Y., Di Patre P.L., Burkhard C., et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004, 108(1):49-56.
7. Claus E.B., Black P.M. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer 2006, 106(6):1358-1363.
8. Thon N., Eigenbrod S., Kreth S., et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 2012, 118(2):452-460.
9. Houillier C., Mokhtari K., Carpentier C., et al. Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas. Neuro Oncol 2009, 12(1):2-6.
10. van den Bent M.J., Afra D., de Witte O., et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005, 366(9490):985-990.
11. Shaw E., Arusell R., Scheithauer B., et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. JClin Oncol 2002, 20(9):2267-2276.
12. Karim A.B., Maat B., Hatlevoll R., et al. Arandomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996, 36(3):549-556.
13. Smoll N.R., Gautschi O.P., Schatlo B., Schaller K., Weber D.C. Relative survival of patients with supratentorial low-grade gliomas. Neuro Oncol 2012, 14(8):1062-1069.
14. Smith J.S., Chang E.F., Lamborn K.R., et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. JClin Oncol 2008, 26(8):1338-1345.
15. Kim Y.H., Nobusawa S., Mittelbronn M., et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010, 177(6):2708-2714.
16. Kesari S., Schiff D., Drappatz J., et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 2009, 15(1):330-337.
17. Choi C., Ganji S.K., DeBerardinis R.J., et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012, 18(4):624-629.